- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01730352
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
November 20, 2012 updated by: Elisabete Kawakami, Federal University of São Paulo
Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial
The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura (ITP), and there is scientific evidence for the investigation and treatment of this bacterium for adult patients with ITP.
However, in children this causal association is not clear, with few published studies.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sao Paulo, Brazil, 01221-020
- Irmandade da Santa Casa de Misericordia se Sao Paulo
-
Sao Paulo, Brazil, 01401-000
- Centro de Hematologia de Sao Paulo
-
Sao Paulo, Brazil, 04021-001
- Federal University of São Paulo
-
Sao Paulo, Brazil, 05614-040
- Hospital Estadual Infantil Darcy Vargas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 20 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- clinical diagnosis of chronic immune thrombocytopenic purpura
- children and adolescents up to 20 years
Exclusion Criteria:
- known hypersensitivity to any of the drugs
- recent treatment for H. pylori eradication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: H. pylori no treatment
Observational group, with clinical and platelet count follow-up
|
|
Experimental: H. pylori triple therapy
Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
|
Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
platelet response
Time Frame: 1 year
|
Responders: Complete Response (CR), persistent elevation of platelet count to >150×109/L; Partial Response (PR), elevation between 20 and 30×109/L above the baseline values, but between 50 and 149×109/L; No Responders: any of the above categories.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elisabete Kawakami, Professor, Federal University of São Paulo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
November 15, 2012
First Submitted That Met QC Criteria
November 20, 2012
First Posted (Estimate)
November 21, 2012
Study Record Updates
Last Update Posted (Estimate)
November 21, 2012
Last Update Submitted That Met QC Criteria
November 20, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Infections
- Purpura
- Purpura, Thrombocytopenic
- Helicobacter Infections
- Purpura, Thrombocytopenic, Idiopathic
Other Study ID Numbers
- 08/56706-0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on H. pylori triple therapy
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions and other collaboratorsCompleted
-
Sohag UniversityCompletedEpilepsy, Generalized | Helicobacter Pylori InfectionEgypt
-
Fudan UniversityRecruitingHelicobacter Pylori Infection | MALT Lymphoma of StomachChina
-
University of WashingtonNational Institutes of Health (NIH)Completed
-
Sohag UniversityNot yet recruitingIrritable Bowel Syndrome
-
BioRed LLCUnknownWater-Related DiseasesPeru
-
Ziauddin UniversityCompletedHelicobacter Pylori InfectionPakistan
-
Centro Hospitalar e Universitário de Coimbra, E...University of CoimbraRecruitingImmunology | Gut Microbiota | Helicobacter PyloriPortugal
-
Seattle Institute for Biomedical and Clinical ResearchEisai Inc.; PriCara, Unit of Ortho-McNeil, Inc.CompletedIron Deficiency Anemia | Helicobacter Pylori InfectionUnited States
-
Seoul National University Bundang HospitalRecruiting